Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of bortezomib in treating young
patients with refractory or recurrent leukemia. Bortezomib may stop the growth of cancer
cells by blocking the enzymes necessary for their growth.